ICR completes new deal with company to develop ovarian cancer drug CT900 11 Oct 2018 The Institute of Cancer Research, London and global healthcare company BTG have successfully concluded negotiations with a biopharmaceutical company, Carrick Therapeutics, to take a promising precision drug discovered at The Institute of Cancer Research into a later-stage clinical trial. Find out more Show/Hide
ASCO 2017: Ovarian cancer drug delivers ‘very promising’ results in early trial 03 Jun 2017 A new targeted treatment for ovarian cancer has shown ‘very promising’ results in an early clinical trial – shrinking tumours in half of women with the disease. Find out more Show/Hide